PROMISE: Spinal Cord Stimulation Versus Instrumentation for FBSS

Sponsor
University Hospital Augsburg (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05466110
Collaborator
Boston Scientific Corporation (Industry)
84
2
30.1

Study Details

Study Description

Brief Summary

Low back pain affects people of all ages and has become the leading cause of living with disability worldwide. Patients, suffering from persistent pain after spinal surgery in the absence of any clear spinal pathology are defined of having a "failed back surgery syndrome (FBSS)" and treatment of FBSS remains a great controversy in the spinal community. Apart from conservative treatment, spinal fusion remains as therapeutic option. Furthermore, minimal invasive Neuromodulation techniques might be a promising alternative. Aim of this randomized interventional multi center study is to compare treatment success in FBSS patients with either spinal cord stimulation (SCS) or fusion surgery, 12 months after intervention according to the Oswestry Disability Index (ODI) and other scales and scores. Radiological and health economic outcome also will be analysed for thorough comparison of techniques. Additionally, the safety of the interventions needs to be compared.

Condition or Disease Intervention/Treatment Phase
  • Device: Spinal Cord Stimulation
  • Procedure: Spinal Fusion Surgery
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
84 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
sPinal coRd stimulatiOn coMpared With Lumbar InStrumEntation for Low Back Pain After Previous Lumbar Decompression (PROMISE): a Prospective Randomized Controlled Study
Anticipated Study Start Date :
Jul 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jan 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Spinal Cord Stimulation Device

The spinal cord stimulators WaveWriter AlphaTM (Boston Scientific) are designed to treat chronic back or leg pain by electrically stimulating the spinal cord. It is a well established worldwide licensed device. Percutaneous lead(-s) are implanted in the epidural space of the thoracic spine during the initial procedure. After discharge a trial phase is initiated and performed according to local preferences and standard of operations (SOPs). Patients are monitored for any complications and pain reduction. If a significant pain reduction (>50 % on the NRS scale for back pain) is achieved, the permanent implantable pulse generator (IPG) is implanted. Otherwise if the therapy remains non-beneficial throughout the trial phase, the leads will be explanted. Patients are allowed to crossover in the fusion group at any point of time.

Device: Spinal Cord Stimulation
Epidural application of electrical current to the spinal cord
Other Names:
  • SCS
  • Active Comparator: Control - Lumbar Fusion surgery

    The control group needs to represent the standard of care of current practice. Gold standard is lumbar fusion surgery [Resnik 2005]. Surgical instrumentation will be performed according to local preferences and SOPs. Safety and efficacy of these fusion techniques have been repeatedly proven

    Procedure: Spinal Fusion Surgery
    screw-rod system based spinal instrumentation

    Outcome Measures

    Primary Outcome Measures

    1. Oswestry disability index / ODI [12 months after intervention]

      A patient reported outcome measure to rate pain and disability

    Secondary Outcome Measures

    1. Adverse events [12 months after intervention]

      Comparison of complication rates

    2. SF36 [12 months after intervention]

      Score to assess quality of life

    3. EuroQOL 5D [12 months after intervention]

      Score to assess quality of life

    4. hospital length of stay [through study completion, an average of 2 years]

      Time measured in days, counting from the first day of hospitalization until the day of discharge of the hospitalization the surgical intervention was performed. If surgery is performed as staged procedure in two separate hospitalizations (SCS) both hospitalizations are counted as described above and days are summed up.

    5. Crossover rates [12 months after intervention]

      Rates of crossover to another therapy arm

    6. Pain medication [12 months after intervention]

      Amount of analgesics taken (drug, dose, mode of application)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age ≥18 years

    • Symptomatic degenerative disc disease with LBP as a predominant symptom for at least 6 months following pervious surgery for disc herniation

    • ODI score at least 21

    • Correctly signed informed consent form

    Exclusion Criteria:
    • Spinal stenosis resulting in spinal claudication or neurological deficits

    • Spinal Instability (> 3 mm Motion on dynamic Lumbar X-rays)

    • Major psychiatric disorder

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University Hospital Augsburg
    • Boston Scientific Corporation

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospital Augsburg
    ClinicalTrials.gov Identifier:
    NCT05466110
    Other Study ID Numbers:
    • 22-0221
    First Posted:
    Jul 20, 2022
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Apr 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 20, 2022